. Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):557-8. PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)
Cohort
(N)
Measurement
Mean ± SD
Method;
Assay Name;
Manufacturer
Diagnostic
Criteria
Aβ42
(CSF)
AD
(35)
748 ± 297
pg/mL
ELISA;
Innotest;
Innogenetics
McKhann et al., 1984
Aβ42
(CSF)
CTRL-
CNC
(19)
1623 ± 429
pg/mL
ELISA;
Innotest;
Innogenetics
GFAP
(CSF)
AD
(35)
717 ± 250
pg/mL
ELISA;
Other/Not Specified;
In-house
McKhann et al., 1984
GFAP
(CSF)
CTRL-
CNC
(19)
860 ± 297
pg/mL
ELISA;
Other/Not Specified;
In-house
NFL
(CSF)
AD
(35)
615 ± 456
pg/mL
ELISA;
Other/Not Specified;
In-house
McKhann et al., 1984
NFL
(CSF)
CTRL-
CNC
(19)
295 ± 194
pg/mL
ELISA;
Other/Not Specified;
In-house
NSE
(CSF)
AD
(35)
7.4 ± 2.7
ng/mL
ELISA;
Other/Not Specified;
Sangtec Medical
McKhann et al., 1984
NSE
(CSF)
CTRL-
CNC
(19)
6.9 ± 2.1
ng/mL
ELISA;
Other/Not Specified;
Sangtec Medical
tau-total
(CSF)
AD
(35)
634 ± 288
pg/mL
ELISA;
Innotest;
Innogenetics
McKhann et al., 1984
tau-total
(CSF)
CTRL-
CNC
(19)
375 ± 171
pg/mL
ELISA;
Innotest;
Innogenetics

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.